CICERO, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the third quarter 2025. THIRD QUARTER 2025 RESULTS(As compared to the third quarter 2024)Total revenue of $44.2 million, +25% y/y GAAP net income of $7.5 million, or $0.32 per diluted share Non-GAAP Adjusted EBITDA of $2.4 million, excluding the $8.2 million gain on the sale of industrial fabrication operations on September 8, 2025 Total orders of $43.6 million, +90% y/y Raising full-year 2025 revenue guidanceMANAGEMENT COMMENTARY “This year, our team continued to transform Broadwind into a leading precision manufacturing partner of choice to global OEMs,” stated Eric Blashford, President and CEO of Broadwind....

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress:Energy Based Device (“EBD”) revenues showing signs of stabilization.Total EBD systems sales of $9.6 million, up 2% year over yearTotal revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter.Primarily driven by a decline in the Hair Restoration business (the “Venus Hair Business”) impacted by a delay in the pending sale.Third quarter GAAP net loss of $22.5 million, compared to $9.3 million last year. Excluding loss on debt extinguishment, loss on disposal of subsidiaries and restructuring...

Accelerating profitable growth and building a new TAD tissue facility to start-up in 2028 MISSISSAUGA, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2025 financial and operational results of KPT and Kruger Products Inc. (Kruger Products or the Company). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and Bonterra®) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.1% interest in Kruger Products. Kruger Products Q3 2025 Business and Financial HighlightsRevenue was $561.1 million in Q3 2025 compared to $521.1 million in Q3 2024, an increase...

Very strong order momentum, with third quarter order intake up 33% year-over-year Order backlog increased by another 6% since June 2025, supporting 2026 growth ambitions Group net sales of $471m, up 3% year-over-year, with expected significant growth in fourth quarter Adjusted EBITDA1 of $42.2m or 9.0% adjusted EBITDA margin, up 25% year-over-year with a 160 basis-point margin improvement Synergies materialization accelerated, supporting upper end of increased target of $40mFRAUENFELD, Switzerland,, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aebi Schmidt Group (NASDAQ: AEBI) (“Aebi Schmidt” or the “Company”), a world-class specialty vehicles leader, reports significant step-up in profitability following the acquisition of the Shyft Group. “The entire new Aebi Schmidt Group has been focusing on executing the integration and realizing the...

The Company Achieves a 7% Increase in YTD Production, Reduces Net Debt, and Maintains Production and Capital Expenditure Guidance Ranges CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bonterra Energy Corp. (TSX: BNE) (“Bonterra” or the “Company”) is pleased to announce its financial and operating results for the three and nine months ended September 30, 2025. The related unaudited condensed financial statements and notes for the third quarter, as well as management’s discussion and analysis (“MD&A”), are available on SEDAR+ at www.sedarplus.ca and on Bonterra’s website at www.bonterraenergy.com. FINANCIAL AND OPERATIONAL HIGHLIGHTS    Three months ended Nine months endedAs at and for the periods ended ($ 000s except for $ per share and $ per BOE) September 30,2025   September 30,2024 September 30,2025   September...

Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights for its antiviral programs. Recent Highlights and Anticipated Milestones: Product Development Ratutrelvir (COVID): Potential best-in-class therapy to minimize the risk of viral...

Entered into an Agreement to be acquired by QOL Medical Net product sales for the third quarter of 2025 reached $4.3 million; up 61% year-over-year Gimoti patent life for Gimoti extended through November 2038 SOLANA BEACH, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “The proposed transaction with QOL Medical reflects this progress and the strategic value we’ve built around GIMOTI and across the broader GI community,” commented Matt D’Onofrio, Chief Executive Officer of Evoke Pharma. “We are proud of the consistent execution that led to...

Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025 Fondazion Melanoma Onus will sponsor a new clinical trial (NEO-CYT) at up to 12 cancer centres in Italy to evaluate if MDNA11 in combination with leading check-point inhibitors, prior to surgery (neoadjuvant), can improve outcomes in patients with earlier stage high-risk melanoma MDNA113, Medicenna’s first-in-class tumor-anchored and masked anti-PD-1 x IL-2 bispecific program, is being evaluated in non-human primate studies, with plans for a first-in-human clinical trial to commence in 2026 Six new patents have been issued or allowed across multiple jurisdictions (US, Japan, Canada and Australia) protecting several superkine assets including its wholly-owned anti-PD1...

First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“’2510”) monotherapy in adult patients with advanced solid tumors DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update. Recent Highlights:In September, ImmuneOnco, Instil’s collaborator, presented updated data from additional patients with relapsed/refractory squamous non-small cell lung cancer treated with ‘2510 as monotherapy in a poster presentation at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. In October, Axion Bio, Instil’s subsidiary, dosed the first patient in its Phase...

Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “In the third quarter, we remained focused on clinical execution in both our global Phase 3 CoMpass trial in early choroidal melanoma and our Phase 1b/2 trial in NMIBC,”...